FDA Approves Cimzia for Crohn's Disease Treatment

Yesterday the FDA approved a new drug for the treatment of Crohn's Disease. Read the full story from the FDA website. The drug, Cimzia, was approved for adults with moderate to severe Crohn's disease and who have not responded to conventional therapies.

The FDA website states, "Patients treated with Cimizia will receive an injection every two weeks for the first three injections. Once benefit has been established, Cimizia should be given once every four weeks."

The article also warns of Cimzia's possible side effects which include, "headache, upper respiratory infections, abdominal pain, injection site reactions and nauseau."

Cimzia's approval comes on the heels of the recent FDA approval of Tysabri for Crohn's Disease. Read expert, Elizabeth Roberts, post "Tysabri Approved for Some Crohn's Patients" for more information on Tysabri's approval.